0,1,2,3,4
Table 6.5.3: Randomised controlled phase II/III - second-line/third-line trials in mCRPC,,,,
Study  Intervention  Comparison  Selection criteria  Main outcomes,,,,
ABIRATERONE,,,,
COU-AA-301   2012 [1209],abiraterone +   prednisone HR,placebo +   prednisone,Previous docetaxel.   ECOG 0-2.   PSA or radiographic   progression.,"OS: 15.8 vs. 11.2 mo.   (p < 0.0001, HR: 0.74, 95%   CI: 0.64–0.86; p < 0.0001).   FU: 20.2 mo.  rPFS: no change"
COU-AA-301   2011 [1208],,,,OS: 14.8 vs. 10.9 mo.  (p < 0.001 HR: 0.65; 95%   CI: 0.54–0.77).   FU: 12.8 mo.  rPFS: 5.6 vs. 3.6 mo.
Radium-223,,,,
ALSYMPCA   2013 [1211],radium-223,placebo,Previous or no   previous docetaxel.   ECOG 0-2. Two or   more symptomatic   bone metastases. No   visceral metastases.,"OS: 14.9 vs. 11.3 mo.   (p = 0.002, HR: 0.61; 95%   CI: 0.46–0.81).   All secondary endpoints show a   benefit over best SOC."
CABAZITAXEL,,,,
TROPIC   2013 [1246],cabazitaxel +   prednisone,mitoxantrone +   prednisone,Previous docetaxel.   ECOG 0-2.,OS: 318/378 vs. 346/377 events  (OR: 2.11; 95% CI: 1.33–3.33).   FU: 25.5 months OS > 2 yr 27%   vs. 16% PFS: -
TROPIC   2010 [1204],,,,"OS: 15.1 vs. 12.7 mo.  (p < 0.0001, HR: 0.70;   95% CI: 0.59–0.83). FU: 12.8 mo.  PFS: 2.8 vs. 1.4 mo.  (p < 0.0001, HR: 0.74,   95% CI: 0.64-0.86)"
CARD   2019 [1169],cabazitaxel   (25 mg/m2 Q3W)   + prednisone   + G-CSF,ARTA:   abiraterone +   prednisone   OR  enzalutamide,Previous docetaxel.  Progression < 12 mo.   on prior alternative   ARTA (either before   or after docetaxel),"Med OS 13.6 vs. 11.0 mo.   (p = 0.008, HR: 0.64, 95%   CI: 0.46–0.89).   rPFS 8.0 vs. 3.7 mo.   (p < 0.001, HR: 0.54,   95% CI: 0.40–0.73).  FU: 9.2 mo."
ENZALUTAMIDE,,,,
AFFIRM   2012 [1210],enzalutamide,placebo,Previous docetaxel.   ECOG 0-2.,"OS: 18.4 vs. 13.6 mo.  (p < 0.001, HR: 0.63; 95%   CI: 0.53–0.75).   FU: 14.4 mo.  rPFS: 8.3 vs. 2.9 mo.  (HR: 0.40; 95% CI: 0.35–0.47,   p < 0.0001)."
PARP inhibitor,,,,
"PROfound  2020 [1166,   1167, 1247]",olaparib,abiraterone +   prednisolone or   enzalutamide;  cross-over   allowed at   progression,"Previous ARPI,   alterations in HRR   mutated genes","rPFS: 7.39 vs. 3.55 mo.   (p < 0.0001, HR: 0.34; 95%    CI: 0.25–0.47), conf. ORR    33.3% vs. 2.3% (OR 20.86, 95%   CI: 4.18–379.18).  OS: 19.1 mo vs. 14.7 mo.   (in pts with BRCA1/2, ATM   alterations)  (p = 0.0175; HR 0.69, 95%   CI: 0.5–0.97)."
Radioligand therapy,,,,
VISION   2021 [1229],177Lu-PSMA-617  SOC,SOC alone,Previous at least    1 ARPI and one or   two taxane regimens;  Mandatory: PSMA-  positive gallium-68   (68Ga)–labeled   PSMA-PET scan,Imaging-based PFS:   8.7 vs. 3.4 mo.   (p < 0.001; HR 0.40; 99.2%   CI: 0.29–0.57)   OS: 15.3 vs. 11.3 mo.   (p < 0.001; HR 0.62; 95%   CI: 0.5–0.74)
"TheraP   2021 [1220,   1248]","177Lu-PSMA-617  (8.5 GBq   i.v.q 6-weekly,   decreasing   0.5 GBq/cycle;   up to 6 cycles)","177Lu-PSMA-617  1:1   randomisation  cabazitaxel   (20 mg/m2   i.v.q 3-weekly,   up to 10 cycles)","mCRPC post   docetaxel, suitable   for cabaziaxel",PSA reduction of > 50%:  66 vs. 37 PSA responses; 66%   vs. 37% by ITT; difference 29%  (95% CI: 16–42; p < 0.0001;   and 66% vs. 44% by treatment   received; difference 23% [9–37];    p = 0.0016).
